Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe

A. Trama a,*, S. Mallone b, N. Nicolai c, A. Necchi c, M. Schaapveld d,e, J. Gietema f, A. Znaor g,h, E. Ardanaz i,j, F. Berrino a, The RARECARE working group

a Department of Preventive and Predictive Medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy
b Department of Cancer Epidemiology, Istituto Superiore di Sanità, Viale Regina Elena 299, Rome, Italy
c Department of Medicine, Urology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy
d Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
e Comprehensive Cancer Center Netherlands, Plesmanlaan 125, PO Box 9236, 1006 AE Amsterdam, The Netherlands
f Department of Medical Oncology, University Medical Center Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands
g Croatian National Cancer Registry, Croatian National Institute of Public Health, Rockefellerova 7, 10000 Zagreb, Croatia
h Stampar School of Public Health, University of Zagreb Medical School, Rockefellerova 4, 10000 Zagreb, Croatia
i Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública-CIBERESP), Spain
j Navarra Cancer Registry, Navarra Public Health Institute, C) Leyre 15, Pamplona 31003, Spain

ARTICLE INFO

Article history:
Available online 3 December 2011

Keywords:
Rare diseases
Testicular cancer
Paratesticular cancer
Germ cell tumour
Sex cord tumour
Cancer registries
Incidence
Prevalence
Survival

ABSTRACT

We provide updated estimates of survival, incidence, complete prevalence, and proportion cured for patients with testicular/paratesticular and extragonadal germ cell cancers in Europe, grouped according to the new list of cancer types developed by RARECARE. We collected data, archived in European cancer registries, with vital status information available to 31st December 2003.

We analysed 26,000 cases of testicular, paratesticular and extragonadal germ cell cancers diagnosed 1995–2002, estimating that about 15,600 new testicular/paratesticular and 630 new extragonadal cancer cases occurred per year in EU27, with annual incidence rates of 31.5/1,000,000 and 1.27/1,000,000, respectively. Slightly more than 436,000 persons were alive at the beginning of 2008 with a diagnosis of testicular/paratesticular cancer, and about 17,000 with a diagnosis of extragonadal germ cell cancer.

Five-year relative survival was 96% for testicular/paratesticular cancer and 71% for extragonadal germ cell cancer; the proportions cured were 95% and 69%, respectively. We found limited variation in survival between European regions except for non-seminomatous testicular cancer, for which five-year relative survival ranged from 86% in Eastern Europe to 96% in Northern Europe. Survival for all cancer types considered decreased with increasing age at diagnosis.

Further investigation is required to establish the real reasons for the lower survival in Eastern Europe. Considering the high prevalence of these highly curable cancers, it is important to monitor patients long-term, so as to quantify treatment-related risks and develop treatments having limited impact on quality of life.

© 2011 Elsevier Ltd. All rights reserved.